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ABSTRACT
Short-term ventricular assist devices (VADs) are mechanical pumps that are used to
temporarily support a patient who is in cardiogenic shock. These VADs are effective in
sustaining a patient’s life until he or she can been transferred to a tertiary cardiac center
such as the University of Michigan Health System. The researcher examined patients’
clinical status at the time of transfer and used univariate analysis to determine which
factors are likely to predict a successful outcome. Multivariate analysis showed that
younger age and better kidney function were prognostic variables in the patients’ 30-day
and long-term survival. These factors improve the chances of a patient becoming a heart
transplant candidate and increase the probability of long-term survival.
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CHAPTER 1: Introduction
Introduction
Almost 80 million American adults have some form of heart disease, also known as
cardiovascular disease (CVD). Many of these patients can be treated with medications and
lifestyle changes, while others are prone to heart attacks, cardiogenic shock, and heart failure.
Often the only hope of recovery for someone with severe heart failure is heart transplantation or
ventricular assist device (VAD) therapy. However, many hospitals in the United States are not
equipped to handle such operations or care for these patients. Therefore, many patients are not
located near a major cardiac center when their disease progresses or when they are in an
emergency situation. Physicians at smaller hospitals will often use a short-term VAD to stabilize
patients until they can be transported to a tertiary medical center for further treatment. Relatively
few studies have reported on the long-term outcomes of patients supported on short-term VADs
and transferred to a tertiary center. Significantly more data are needed to determine whether
patient selection and improvements in clinical management can improve survival for these
patients. Identification of clinical variables prognostic in patient outcome could be invaluable to
physicians not only at the tertiary centers but the referring hospitals as well. This study is an
analysis of patients transferred to the University of Michigan Health System (UMHS) on a shortterm ventricular assist device from 1997 – 2007.
Background
The heart functions to pump blood to all parts of the body so that oxygen can reach all of
the cells, but there are many diseases and conditions that cause the heart to perform inadequately.
The American Heart Association reports that cardiovascular disease is the leading cause of death
in the United States, resulting in nearly 2400 deaths every day (2007). There are numerous
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forms of CVD including hypertension, coronary heart disease, heart failure, and stroke.
Sometimes these conditions can develop slowly over time and are influenced by genetics as well
as environment. Other forms of CVD can develop more rapidly, such as viral cardiomyopathy or
myocardial infarction.
Many people with heart disease are able to keep their condition under control with
medications and lifestyle changes, such as diet modification and exercise. However, often the
condition progresses and a patient may require a more invasive procedure, such as percutaneous
coronary interventions (PCIs). PCIs include treatments such as angioplasty or stents, which are
performed to open narrow or blocked arteries. Sometimes even PCI is not enough and surgery is
required. One of the most common heart surgeries is coronary artery bypass grafting (CABG),
which involves bypassing clogged arteries with another vessel.
Sometimes heart disease may progress into heart failure, a condition in which the heart
fails to function properly. This can occur suddenly as a result of a myocardial infarction resulting
in cardiogenic shock or can progress in a chronic fashion as a result of an underlying CVD.
Another cause of heart failure occurs when a patient fails to recover adequate heart
function after being on cardiopulmonary bypass during a cardiac operation. This specific
circumstance is called postcardiotomy heart failure. Treatment for heart failure, whatever the
cause, may include surgery, implantation of mechanical assist devices, or heart transplantation.
There are more 2200 heart transplants performed each year in the United States; it is the
fourth most common organ transplanted behind corneal, kidney, and liver transplants (U.S.
National Library of Medicine and National Institutes of Health, 2006). There are many people
on the waiting list for a heart transplant, but often a heart never becomes available due to the
shortage of donor organs. Therefore, many physicians and patients have begun looking for
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alternatives and other therapies to help patients either “hold on” long enough to wait for a heart
or to help their heart recover in the hopes of not needing a heart transplant at all. One such
therapy is the implantation of a VAD.
VADs are mechanical pumps that assist the heart in pumping blood when it is unable to
do so due to heart failure. There are many different types and uses of VADs. Some are
considered temporary and meant for shorter support times of hours or days. Other VADs are
designed for long-term use and may be used for cardiogenic support for months or years. One
common use of long-term VAD is for cardiogenic support while a patient is awaiting heart
transplantation. An example of a temporary VAD is shown in Figure 1. It consists of an external
device that is powered by a pneumatic console and is designed to support one or both of the
ventricles for a short period of time.

Figure 1. – Abiomed BVS5000; a temporary assist device
One major limitation of VAD and heart transplant therapy is that only a limited number
of medical centers are able to provide this treatment. For a patient in a life-threatening situation
and at a medical facility without these capabilities, there are typically few options available to
3

them. Short-term VADs have become more readily available at smaller facilities and are a
feasible treatment for patients in cardiogenic shock. These VADs are designed to support
patients until they can be transferred to a tertiary cardiac center for further treatment, which may
involve recovery, implantation of a long-term VAD, or heart transplantation. This system of
patient transfer is often referred to as a “hub and spoke,” with the tertiary center as the hub
receiving patients from the referring “spoke” hospitals. As more mechanical circulatory support
devices are developed and studied, more centers will be able to report their success with this
treatment, allowing physicians at both large and small hospitals to use the knowledge to better
manage their heart failure patients.
Study Objective
The objective of this study is to identify prognostic variables based on patient
information available within the first 24 hours of transfer to the University of Michigan Health
System that may improve patient care and outcomes.
Study Goal
Suggesting prognostic variables to make patient care decisions to improve outcomes with
short-term mechanical circulatory support is the goal of this research.
Hypothesis
Clinical characteristics of the patient’s status within the first 24 hours of presentation
with temporary VADs have significant prognostic value with respect to short- and long-term
survival.
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CHAPTER 2: Review of Literature
Mechanical pumps are becoming more common in the treatment of heart failure and
cardiogenic shock. They are the subject of many clinical trials, most of which are designed to
study the safety and effectiveness with the newer generations of VADs. Only a few centers have
published their experiences of patients who are transferred to their institution from the referring
hospital, commonly referred to as the “hub and spoke system.”
Helman et al. (1999) published findings from Columbia-Presbyterian Medical Center
after they established a referral network for patients who were potentially in need of a long-term
VAD. They reported on 44 postcardiotomy patients, all of whom were being supported by a
short-term VAD or other cardiogenic support therapies given at an outside hospital. They
reported that 66% of the patients survived to discharge and that utilization of referral networks
may substantially improve survival rates for postcardiotomy heart failure patients.
Years later, Kherani et al. (2003) reported further success of the hub and spoke system at
Columbia-Presbyterian Medical Center. They performed a retrospective review of 46 patients
with acute cardiogenic shock who had been transferred to their facility for further treatment. All
patients received a long-term VAD for treatment, and their survival to discharge rate was 57%.
This study also analyzed organ function tests as possible predictors to survival, although none
were shown to be significant in this study. Not all patients in their study received a VAD at the
spoke hospital, but it concluded that patients in cardiogenic shock may have better outcomes
after referral to a large center.
R. J. Morris et al. (2005) conducted a prospective study of VAD supported patients at the
University of Pennsylvania Hospital from 1997 to 2000. They separated their subjects into two
cohorts: those who received a VAD at their institution (n= 76) or those who were transferred
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from another hospital with a VAD already implanted for cardiac support (n=28). Analysis of
their transferred patients showed a survival rate of 32%. All of these survivors went on to receive
a heart transplant. This study differs from the Columbia experiences because they focused on
only patients with VAD support. However, this study did not have many patients who were
transferred to their hospital and also did not look at long-term survival.
Another study published by Gonzalez-Stawinski et al. (2006) examined the regional
referral system for patients who were transferred to the Cleveland Clinic Foundation with an
acute mechanical support device. This study reported the outcomes and variables that could
influence survival of these patients. Thirty-nine patients were studied in a retrospective review
from 1995-2003. The majority (85%) of the transferred patients were on VAD support, but the
study also included patients who arrived on other types of cardiogenic support. Their survival
rate was calculated to be 38%. Almost half were able to be weaned from support, while the
others received long-term VAD support and/or heart transplantation. They concluded that
patients who had undergone less complex surgical procedures were more likely to survive.
This study seeks to expand our knowledge of patient outcomes after transfer to a tertiary
cardiac center with a short-term VAD for cardiogenic support. Examining patients’ clinical
status upon arrival and examining their survival may identify variables that are important in
predicting survival for future patients. Most of the previous studies have not reported on the
long-term outcomes of these patients, nor did they look at specific clinical variables such as
laboratory tests, hemodynamics, and medications upon arrival.
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CHAPTER 3: Research Design and Methodology
Study Design
This analysis is a single-center retrospective study of patients transferred to UMHS with
a VAD for short-term cardiogenic support. The study was approved by the Eastern Michigan
University Human Subjects Committee and the University of Michigan’s IRBMED prior to data
collection. A waiver of consent was granted for this study.
Study Population
Patients satisfying the study inclusion criteria were identified under the guidance of
UMHS faculty advisor Francis D. Pagani, MD, PhD, Associate Professor of Surgery in the
Section of Cardiac Surgery.
Inclusion/Exclusion Criteria
Subjects were included in this study if they were transferred to UMHS from an outside
hospital after implantation of a short-term cardiac assist device for cardiogenic support. No age
or other physiological limitation was established.
Patients on extracorporeal-membrane oxygenation (ECMO) were excluded from this
study in order to maintain homogeneity of the subject population by eliminating patients who
may be in respiratory failure.
Data Collection
Medical records were obtained for all subjects from the UMHS Health Information
Management Department and the CareWeb system of electronic records at UMHS. Outside
hospital records were reviewed only if they were already part of the patient’s medical record at
UMHS. Intensive Care Unit (ICU) critical care sheets were reviewed for the patients’ first 24
hours at UMHS in order to determine their clinical status at the time of transfer. Variables that
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were captured included, but were not limited to, demographics, medical history, outside hospital
information, clinical status upon transfer, laboratory test results, and hospitalization times.
Patient outcomes were ascertained by review of current medical records or collection of a
death certificate. Patients who had not been seen by a UMHS healthcare member since their
discharge and did not have current information in their medical records were considered alive if
they were not identified in the Social Security Death Index.
Data Analysis
SPSS (SPSS Inc, Version 15.0) and Microsoft Excel were utilized for Data Analysis.
Statistical analysis included examining overall study population characteristics using
mean+standard deviation and proportions. Survival estimates were performed using KaplanMeier analysis. Univariable analysis of dichotomous variables was performed using a chi-square
test. Continuous variables were subjected to univariable analysis by utilizing an independent ttest. Level of significance for inclusion into a multivariable model was defined at p<0.05.
Multivariable analysis was performed by a Cox regression method importing values identified as
significant by univariable analysis. Comparison of survival estimates was done by log rank
analysis.
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CHAPTER 4: Results and Data Analysis
Study Population
Forty-eight patients with a temporary VAD implanted for heart failure at an outside
hospital and transferred to the University of Michigan Health System for further care were the
subject of this analysis. All transfers occurred between September of 1997 and June of 2007. The
age range of all patients was 14-77 years and the median age was 50.9 years. Figure 2 shows the
age distribution of the population.
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Figure 2. Age distribution.
The majority of these patients were Caucasian males in their late forties with ischemic
heart disease and a history of hypertension and myocardial infarction (see Table 1). Analysis of
their medical history showed that 60% of these patients did not have any cardiac procedures
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prior to their implant, while those who had Coronary Artery Bypass Graft (CABG) surgery or
percutaneous coronary interventions (PCI) were 15% and 25%, respectively.
Table 1
Demographics and Medical History
Variable
Overall No. (%)
a
Mean age (years)
49.6 +/- 12.9
Range
14.8 – 77.3
Gender
Male (%)
31 (65%)
Female (%)
17 (35%)
Race
Caucasian (%)
39 (81%)
African American (%)
3 (6%)
Unknown (%)
6 (13%)
Body surface area (M2)a
2.01 +/- 0.24
Body Mass Index
28.99 +/- 4.97
Co-morbidities
Hypertension (%)
30 (63%)
Diabetes (%)
18 (38%)
COPD (%)
3 (6%)
Myocardial infarction (%)
35 (73%)
Etiology
Ischemic (%)
40 (83%)
Nonischemic (%)
8 (17%)
Prior cardiac procedures
None (%)
29 (60%)
b
PCI/PTCA (%)
12 (25%)
CABGc (%)
7 (15%)
a
Mean +/- Standard Deviation.
b
PCI/PTCA = Percutaneous Coronary Interventions / Percutaneous Coronary Angioplasty
c
CABG = Coronary Artery Bypass Graft

Implant Information
All patients presented to an outside hospital for either emergency service or routine care.
During their visit they developed heart failure, and a temporary VAD was implanted for support.
Table 2 shows that the majority of patients came from a large hospital. Experience and
sophistication of medical care at the referring hospital was arbitrarily defined by the number of
cardiac surgical procedures performed yearly at the referring institution. All hospitals were
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located in Michigan or northwest Ohio and frequently refer patients to UMHS, which performs
more than 800 cardiac procedures per year and is a regional transplant center.
Table 2
Information on Implant and Referring Hospital
Variable
Overall No. (%)
a
Referral Hospital
Small (0-200)
1 (2%)
Medium (201-500)
19 (40%)
Large (501+)
27 (56%)
Unknown
1 (2%)
Indication
Cardiogenic Shock
11 (23%)
Postcardiotomyb
37 (77%)
Post-CABG
34 (71%)
Acute MI (< 7 days)
26 (54%)
Type of support
Left (LVAD) only
18 (38%)
Right (RVAD) only
2 (4%)
Both (BiVAD)
28 (58%)
Specific Device
ABIOMED BVS5000
46 (96%)
BioMedicus
2 (4%)
Days from Admission to Implantc
2.06 +/- 2.3
Days from Implant to Transferc
2.1 +/- 3.4
a
Based on number of cardiac procedures performed annually (in parentheses).
b
Implantation occurring ≤ 24 hours after cardiac surgery.
c
Mean +/- Standard Deviation

More than three-fourths of the patients required a VAD for postcardiotomy, which was
defined as heart failure occurring within 24 hours of cardiac surgery. The majority of
postcardiotomy patients were undergoing CABG surgery as treatment for their heart disease at
the time of VAD implantation. More than one-half of all study patients were diagnosed as having
had a heart attack within the seven days prior to receiving their implant.
Temporary VADs can be used to support either one of the ventricles or both ventricles
depending on the severity of the heart failure. Most patients required biventricular support
(BiVAD), meaning that two devices were implanted. The ABIOMED BVS5000 (ABIOMED,
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Inc, Danvers, MA) is a popular device used in small hospitals to support patients in cardiogenic
shock (see Figure 1). All but two of the patients transferred to UMHS were being supported by
the ABIOMED BVS5000.
Clinical Status upon Presentation to UMHS
In order to identify variables that may be prognostic of survival, it was important to
investigate the condition of a patient upon arrival from the referring hospital. Data were collected
as close to transfer as possible. Table 3 shows the overall characteristics of this population
including vital signs, hemodynamics, pump parameters, medication requirements, and other
clinical factors.
The results show that every patient was in need of ventilator support (100%). Data on
ventilator mode and rate were collected as well as PEEP and FiO2 requirements. Intra-aortic
balloon pumps (IABP) are devices placed in the aorta that increase blood flow to the heart. They
are often used alone but may be used in combination with a VAD. One-fourth of the patients in
this study arrived with an IABP in place.
Organ failure is a common risk of heart failure. When the kidneys are not functioning
properly, dialysis is required. One type of dialysis used in these situations is continuous venovenous hemofiltration (CVVH). Analysis showed that 23% of these patients required CVVH
within the first 24 hours of presentation to UMHS.
Medication requirements upon arrival were collected from each patient’s ICU flow sheet.
Three categories of medications were used in this analysis. Inotrope medications help the heart
beat stronger when it is incapable of doing so on its own. Vasoconstrictors contract the smooth
muscle in blood vessels, causing them to constrict and restrict blood flow. Vasodilators
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Table 3
Patient Status upon Arrival at UMHS
Variable
Vital Signs/Hemodynamics
Heart Rate (bpm)
Mean Systolic Blood Pressure
Temperaturea (C)
Pulmonary Artery Pressure
Central Venous Pressure
Cardiac Output
LVAD flow (L/min)
RVAD flow (L/min)
Heart Rhythm
Sinus
Paced
Atrial fibrillation
Ventricular fibrillation
Arterial Blood Gases
O2 Saturation (%)
pO2
pCO2
pH
Ventricular Support Required
Ventilator Rate (breaths/min)
Ventilator Mode
AC
IMV
PEEP (cmH2O)
FiO2 (%)
Intra-aortic Balloon Pump (IABP)
Medication requirements
Inotropes
Vasoconstrictors
Vasodilators
Chest tube output (mL)b
Urine output (mL)b
Dialysis (CVVH)c

Value
89.0 +/- 22
86.1 +/- 21
37.2 +/- 0.8
28.3 +/- 11
18.7 +/- 8
4.9 +/- 1.1
4.6 +/- 0.7
4.6 +/- 0.9
32 (67%)
8 (17%)
3 (6%)
1 (2%)
93.4 +/- 6.1
143.4 +/- 111
36.8 +/- 7.5
7.41 +/- 0.1
48 (100%)
13.65 +/- 3.7
20 (41.7%)
26 (54.2%)
6.47 +/- 2.3
87.5 +/- 20.6
12 (25%)
28 (58.3%)
25 (52.1%)
12 (25.0%)
537 +/- 483
1207 +/- 1276
11 (22.9%)

a

Tmax over first 24 hours.
Over first 8 hours at UMHS.
c
Within first 24 hours at UMHS.
b
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act by opening blood vessels, which allows for more blood flow. More than half of the patients
were on inotropic and/or vasoconstrictor support, while only 25% were on vasodilator support.
In addition to these clinical characteristics, laboratory values upon arrival were also
explored. Those studied were chemistry panels, liver function tests, hematology, and
coagulation. These tests are routinely done when a patient is brought to the hospital. Table 4
shows the mean, standard deviation, median, and range for the patient population.
Table 4
Laboratory Values upon Transfer to UMHS
Test
Chemistry Panel
Sodium (mMOL/L)
Potassium (mMOL/L)
Chloride (mMOL/L)
Bicarbonate (mMOL/L)
Urea Nitrogen (mg/dL)
Creatinine (mg/dL)
Glucose (mg/dL)
Calcium (mg/dL)
Phosphorus (mg/dL)
Protein – total (g/dL)
Liver Function
Albumin (g/dL)
Aspartate Amino Transferase (IU/L)
Alanine Amino Transferase (IU/L)
Lactic Acid Dehydrogenase (IU/L)
Alkaline phosphatase (IU/L)
Total Bilirubin (mg/dL)
Hematology
White Blood Cell Count (K/MM3)
Hematocrit (%)
Hemoglobin (g/dL)
Platelet Count (K/MM3)
Coagulation
Prothrombin Time (sec)
International Normalized Ratio
Partial Thromboplastin Time (sec)

Mean

SD

Median

Range

140.5
4.29
108.3
25.42
25.6
1.67
145.4
7.35
4.53
4.25

6.31
0.813
5.86
3.6
12.23
0.88
56.2
0.96
2.17
0.8

141.5
4.2
108.5
26.0
23.0
1.4
141.5
7.4
4.0
4.3

128 - 156
2.4 - 6.5
93 - 121
18 - 33
8 - 60
0.4 - 4
71 - 367
5.6 - 9.6
1.6 - 14.5
2.5 - 5.9

2.09
1007
365.3
1884.8
66.62
2.21

0.51
1592.8
646.8
2307
52.11
2.41

2.0
379.0
89.0
936.5
50.0
1.2

1.2 - 3.5
25 - 7132
20 - 2797
292 - 8994
25 - 322
0.4 -12.1

11.79
32.24
11.18
104.6

4.89
4.57
1.51
49.25

11.5
31.9
10.9
97.0

0.9 - 22.9
22.8 - 46.6
7.9 - 15.9
31 - 231

15.7
1.56
63.18

13.5
1.4
29.62

12.3
1.2
53.7

10 - 100
0.9 - 10.1
23.4 - 100
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Overall Survival
Data captured from patient demographics, medical history, implant information, and
clinical condition upon arrival all provide a clearer understanding of the condition in which these
patients arrived for further care at UMHS.
After analysis of the patient’s clinical condition, overall survival was examined. Twentyeight of the patients had their deaths confirmed by the medical records. Thirteen patients were
currently under the care of a UMHS physician and considered alive. The remaining seven
patients were searched for in the Social Security Death Index. This national database was
evaluated by Cowper, Kubal, Maynard, and Hayes (2002) and found to be a reputable source for
researching morality. Two patients were listed as expiring. The remaining five patients were
considered to be alive as of September 2007 and considered alive for data analysis. Median
duration of follow-up for all patients was 18 days and survival to discharge from UMHS was
calculated as 46%.
Figure 3 shows the Kaplan-Meier analysis of survival for all 48 patients following their
temporary VAD implant. The analysis shows that the population appears to be divided into two
roughly equal groups: those who die very soon after implant account for 54% of the population,
and those who go on to live past 30 days after implant account for 46%.
The next step in the data analysis was to determine if any variables were significant
between these two groups.
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Figure 3. Kaplan-Meier plot of survival in all patients.
Identification of Prognostic Variables of Survival at 30 Days Post-Implant
Univariable analysis was performed on all data points to determine which variables
should be incorporated into a multivariable analysis to identify those factors prognostic of a
patient’s survival after implant. The population was separated into two groups for comparison:
those who survived 30 days after implant of their temporary VAD (N=22) and those patients
who expired prior to 30 days (N=26).
Table 5 shows the univariate analysis results of demographics and medical history. Age
at the time of implant (p= 0.001) and a history of diabetes (p=0.000) were shown to be
significant.
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Table 5
Univariable Analysis of Demographics and Medical History for Those Surviving
30 Days Post Implant.
30 Days Post Implant
Variable
Mean age (years)a
Gender
Male
Female
Race
Caucasian
African American
Unknown
Body Surface Area (M2)a
Body Mass Index (kg/m2)
Co-morbidities
Hypertension
Diabetes
COPD
Myocardial infarction
Etiology
Ischemic
Nonischemic
Prior cardiac procedures
None (%)
PCI/PTCA (%)
CABG (%)

Survivors
43.2+/-12.6

Nonsurvivors
55.1 +/- 10.5

p
0.001

12
10

19
7

0.232
0.258

b

19
2
1
1.96 +/- 0.23
27.95 +/- 4.68

20
1
5
2.06 +/- 0.25
29.86 +/- 5.12

0.167
0.186

13
2
1
17

17
16
2
18

0.768
0.0001
1.000
0.746

16 (73%)
6 (27%)

24
2

0.119

14
6
2

15
6
5

0.608

a

Calculated as √[(height in cm*weight in kg)/3600]
Calculated as weight in kg/(height in m)2

b

Information about the referring hospital and data relative to VAD implantation were also
analyzed to determine if any of these factors might be predictive of a patient’s status at 30 days
(see Table 6). None of these variables were shown to be significant predictors of 30-day survival.
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Table 6
Univariable Analysis of Implant and Referring Hospital for Short-term Survival
30 Days Post Implant
Variable
Referral Hospital
Small (0-200)
Medium (201-500)
Large (501+)
Unknown
Indication
Cardiogenic Shock
Postcardiotomyb
Post-CABG
Type of support
Left (LVAD) only
Right (RVAD) only
Both (BiVAD)

Survivors

Nonsurvivors

0
7
14
1

1
12
13
0

16
6
13

21
5
21

11
1
10

7
1
18

Days from Admission to Implant

1.5 +/- 1.77

2.54 +/- 2.56

0.116

Days from Implant to Transfer

2.5 +/- 4.8

1.8 +/- 1.44

0.488

p
0.385

0.732
0.122
0.239

Clinical variables upon arrival were explored to determine if any were significant in a
patient’s survival at 30 days post-implant (see Table 7). Only two variables were calculated as
being significant. One was the requirement for vasoconstrictor medications (p= 0.039). The
other was the need for dialysis, specifically CVVH, within the first 24 hours at UMHS
(p=0.006).
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Table 7
Univariable Analysis of Variables Indicating Clinical Status upon Arrival
30 Days Post Implant
Variable
Vital Signs/Hemodynamics
Heart Rate (bpm)
Mean Systolic Blood Pressure
Temperaturea (C)
Pulmonary Artery Pressure
Central Venous pressure
Cardiac output
LVAD flow (L/min)
RVAD flow (L/min)
Heart Rhythm
Sinus
Paced
Atrial fibrillation
Ventricular fibrillation
Arterial Blood Gases
O2 Saturation (%)
pO2
pCO2
pH
Ventricular Support
Ventilator Rate (breaths/min)
PEEP (cmH2O)
Ventilator Mode
AC
IMV
FiO2 (%)
Intra-aortic Balloon Pump
Medication requirements
Inotropes
Vasoconstrictors
Vasodilators
Chest tube output (mL)b
Urine output (mL)b
Dialysis (CVVH)c

Survivors

Nonsurvivors

p

94 +/- 20
88 +/- 19
37.2 +/- 1.1
26.2 +/- 9.7
18.9 +/- 7.0
4.66 +/- 0.7
4.59 +/- 0.7
4.61 +/- 0.9

85.3 +/- 23
85 +/- 23
37.2 +/- 0.6
29.7 +/- 11.1
18.6 +/-8.8
5.03 +/- 1.4
4.68 +/- 0.7
4.62 +/- 0.9

0.211
0.620
0.884
0.394
0.924
0.297
0.714
0.993
0.672

14
3
1
1

18
5
2
0

94.4 +/- 4.9
129.9 +/- 72.6
37.0 +/- 6.0
7.42 +/- 0.1

92.6 +/- 7.0
154.8 +/- 135.6
37.0 +/- 8.7
7.40 +/- 0.1

0.304
0.445
0.896
0.497

12.5 +/- 2.4
6.3 +/- 2.1

14.5 +/- 4.3
6.6 +/- 2.5

0.062
0.671
0.377

7
13
85.5 +/- 22.6
3

13
13
89.2 +/- 19.0
9

0.532
0.095

13
7
6
560 +/- 558
1079 +/- 967
1

15
18
6
523 +/- 558
1289 +/- 1453
10

0.543
0.039
0.734
0.817
0.614
0.006

a

Tmax over first 24 hours.
Over first 8 hours at UMHS.
c
Within first 24 hours at UMHS.
b
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Values of laboratory blood tests were also tested in a univariable analysis, and the results
are shown in Table 8. Univariate analysis showed that lower serum creatinine levels are
significant (p=0.0001) in those that survive 30 days. Creatinine levels are used to determine
kidney function, and a creatinine level of 0.7-1.3 mg/dL is considered normal. Two of the liver
function tests were also shown to be significant by univariable analysis. AST (asparatate amino
transferase) levels, which are often elevated in patients with cardiac disease, were significantly
lower in survivors (p=0.041). The other significant test was LDH level (p=0.018), which is a
measure of the amount of lactic dehydrogenase in the serum and an indicator of tissue damage.
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Table 8
Univariable Analysis of Laboratory Variables
30 Days Post Implant
Variable
Chemistry Panel
Sodium (mMOL/L)
Potassium (mMOL/L)
Chloride (mMOL/L)
Bicarbonate (mMOL/L)
Urea Nitrogen (mg/dL)
Creatinine (mg/dL)
Glucose (mg/dL)
Calcium (mg/dL)
Phosphorus (mg/dL)
Protein – total (g/dL)
Liver
Albumin (g/dL)
AST(IU/L)
ALT (IU/L)
LDH (IU/L)
Alkaline phosphatase (IU/L)
Total Bilirubin (mg/dL)
Hematology
White Blood Cell Count (K/MM3)
Hematocrit (%)
Hemoglobin (g/dL)
Platelet Count (K/MM3)
Coagulation
Prothrombin Time (sec)
International Normalized Ratio
Partial Thromboplastin Time (sec)

Survivors

Nonsurvivors

p

139 +/- 5.6
4.1 +/- 0.7
108 +/- 6.6
25.8 +/- 3.5
22.9 +/- 11.3
1.19 +/- 0.46
130.6 +/- 40.0
7.1 +/- 0.7
4.5 +/- 1.6
4.4 +/- 0.7

142 +/- 6.8
4.4 +/- 0.9
108 +/- 5.3
25.1 +/- 3.7
28.0 +/- 12.7
2.07 +/- 0.96
157.9 +/- 65.1
7.5 +/- 1.1
4.5 +/- 2.8
4.1 +/- 0.9

0.195
0.170
0.939
0.534
0.149
0.000
0.094
0.120
0.962
0.329

2.11 +/- 0.4
503.7 +/- 602
211 +/- 346
976 +/- 541
75.1 +/- 71.8
1.61 +/- 1.8

2.07 +/- 0.6
1449.9 +/- 2027
501+/- 810
2635 +/- 2894
59.2 +/- 24.0
2.74 +/- 2.8

0.782
0.041
0.126
0.018
0.301
0.110

11.4 +/- 3.9
32.2 +/- 5.1
11.1 +/- 1.7
118.5 +/- 43.4

12.1 +/- 5.7
32.6 +/- 4.2
11.2 +/- 1.4
92.8 +/- 51.6

0.593
0.967
0.873
0.071

12.9 +/- 3.1
1.27 +/- 0.35
59.8 +/- 29.1

18.0 +/- 17.9
1.8 +/- 1.86
66.0 +/- 30.2

0.193
0.189
0.473

Multivariate Analysis to Determine Prognostic Variables of 30-Day Survival
Multivariate analysis was performed using those variables that were significant in the
univariate analysis for 30 day survival. These variables are shown in Table 9. Variables that
remained significant were age (p=0.015) and creatinine levels (p=0.004).
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Table 9
Multivariable Analysis of Variables Identified in Univariable Analysis of 30-Day Survival
30 Days Post Implant
Survivors
(N=22)

Nonsurvivors
(N=26)

p

43+13

55+11

0.015

2 (11%)

16 (53%)

0.087

Dialysis (CVVH)

1 (5%)

10 (38%)

0.350

Vasoconstrictors

7 (32%)

18 (69%)

0.096

Creatinine

1.2+0.5

2.1+1.0

0.004

AST

503+601

1449+2027

0.510

LDH

976+540

2635+2894

0.196

Variable
Demographics/Medical History
Age
Diabetes
Other support

Laboratory values

Long-term Survival Based on Age and Serum Creatinine Levels
As previously shown, 54% of the patients transferred to UMHS with a temporary VAD
did not survive 30 days after implant. Age and serum creatinine levels were shown to be
significant prognostic variables of this survival based on multivariable analysis. Figure 4 shows a
Kaplan-Meier analysis comparing patients who are younger or older than the median age of 50.9.
Statistical analysis reveals the survival of those younger than 50.9 to be significantly
longer than those older than 50.9 (p=0.001).
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Figure 4. Long-term survival dichotomized by median age
Creatinine levels were shown to be significant for 30-day survival. Kaplan-Meier analysis
of the quartiles is shown in Figure 5. Patients with a creatinine level less than 1.0 mg/dl had an
excellent chance of surviving not only 30 days after their implant, but also long term. None of
the 13 patients with poor kidney function, as evidenced by their high creatinine levels (≥ 2.2
mg/dl), survived past 30 days.
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Figure 5. Long-term survival of patients based on serum creatinine levels (grouped by quartiles)
Patient Outcomes
Twenty patients in this study died while still on short-term mechanical support after
being transferred to UMHS for further care. The six remaining patients who did not survive 30
days were either weaned (N=3) or received a more permanent VAD (N=3) but ultimately died
from complications of their heart failure. A flowchart of all patient outcomes is shown in Figure
6.
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Died on
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N=20
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N=12

VAD*
N=16

N=12

Transplant
N=13

N=1

Died
N=3
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< 30 days
survival
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Alive at
30 days
N=9

Died
N=1

Died
N=3

Alive
N=7

Alive
N=1

Died
N=3

Alive
N=10

*Long-term VADS
Figure 6. Patient outcomes (as of 09/17/2007)
Of the 22 patients who survived past 30 days post-implant, 16 went on to receive a longterm VAD. Thirteen of the survivors ultimately received a heart transplant, and 10 of the
transplant recipients are still alive.
Further analysis of current survival revealed that most have lived past one year (see
Figure 7). In addition, 82% (n=18) of those surviving 30 days post-implant are currently alive
with the potential of living greater than 5 years and perhaps more.
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Figure 7. Current survival past implant of those surviving >30 days post-implant
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CHAPTER 5: Discussion
Heart failure, either chronic from an underlying cardiovascular disease, or acute, such as
failure to wean from cardiopulmonary bypass after heart surgery or cardiogenic shock from an
MI, can cause sudden death if not treated immediately. Unfortunately, many people are not near
a hospital when treatment is required and even fewer are near a tertiary cardiac center, where
more options are available to them. This study was designed to examine those patients who
received a short-term VAD for treatment of their heart failure at a hospital other than UMHS and
were subsequently transferred to UMHS for further treatment.
The majority of patients in this study were Caucasian males with a median age of 50.9
years, a history of hypertension, myocardial infarction, and ischemic heart disease. Implantation
of a short-term device was required due to postcardiotomy after CABG surgery and required
biventricular support. Upon transfer to UMHS, more than half of them required inotrope therapy
and vasoconstrictors, while less than one fourth required dialysis.
This is similar to the experiences of Gonzalez-Stawinski et al. (2006) at the Cleveland
Clinic Foundation, in which their median age was 51 years and 85% required a temporary VAD
for postcardiotomy. They did report a much smaller percentage with ischemic disease (46%) as
compared to this analysis.
Kaplan-Meier analysis of the UMHS patients in this study showed that just over half died
within the first 30 days after implantation of their short-term device. Gonzalez-Stawinski et al.
(2006) reported their survival rate was 38%, and Morris et al. reported a survival rate of 32%.
Separate centers are likely to have differing experiences, and results cannot necessarily be
considered comparable. In addition, long-term treatments for heart failure are constantly
improving, and the treatment given by the referring centers may impact the survival rate.
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Identification of prognostic variables for short-term survival revealed age and kidney
function, as shown by creatinine levels, as significant. Younger patients presenting to UMHS
with better kidney function were more likely to survive 30 days post-implant. These patients
were also most likely to be eligible for heart transplantation, thereby increasing the likelihood of
long-term survival. Gonzalez-Stawinski et al. (2006) also reported that younger age, less
complex surgery, and organ function were significant factors in their survival analysis.
Previous studies did not examine survival past one year. Patients in this study were very
likely to live more than 5 years after implant if they survived the initial 30 days. The majority of
them received a heart transplant during that time, most likely due to the fact that their younger
age and better kidney function presented them as good candidates for transplant.
Experience at UMHS is consistent with these other reports that have shown that hub and
spoke referral systems increase survival.
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CHAPTER 6: Limitations
This study is a single center’s experience on patients transferred with a short-term VAD
for cardiogenic support. This study does have the limitations of being a retrospective. Some data
elements were found to be missing or incomplete. In addition, this was a small study population,
and some variables may truly be significant when examined in a larger population.
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CHAPTER 7: Conclusion
Patients that go into cardiogenic shock are often treated by implantation of a temporary
VAD at a community hospital. Once implanted, these patients will often be transferred to a
tertiary care center for further treatment as part of a “hub and spoke” referral system.
Identification of prognostic variables significant in survival of these patients could affect
patient care decisions at both the referring and receiving hospital. The experience of previous
patients transferred to the University of Michigan Health System with a temporary VAD for
cardiogenic shock identified two variables that were indicative of survival. Patients who
survived 30 days post-implant were generally younger and had better kidney function as
measured by serum creatinine. The majority of the surviving patients eventually received a
heart transplant, most likely because their younger age and better kidney function greatly
improved their chances of being a transplant candidate and possibly increased their chances
of survival after transplant.
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